A tiny RNA with a big role in melanoma

February 18, 2014
A tiny RNA with a big role in melanoma
Credit:

A Yale-led study has identified a key mechanism in the regulation of gene expression that promotes the proliferation of melanoma cells. The finding opens a possible avenue for development of treatments that target this mechanism. The study appears online Feb. 18 in the journal eLife.

Melanoma is the deadliest form of skin cancer. BRAF and NRAS genetic mutations are known to occur in a very large proportion of melanomas. But although scientists have identified the oncogenic mutations that trigger and their proliferation, the mechanism that causes to transform into cancerous melanoma cells and cause their spread has not been well defined.

The Yale team identified a microRNA called miR-146a that accelerates in activity in the presence of these oncogenes by activating a cancer promoting signaling pathway called Notch.

The authors suggest that Notch and another signaling pathway called MAP kinase, which is activated by these same oncogenes, represent a valuable drug development target. "Our study has identified a new genetic vulnerability in melanoma, and it is likely that simultaneous inhibition of MAP Kinase pathway and NOTCH will emerge as a better therapeutic option to treat patients," said senior author Narendra Wajapeyee, assistant professor of pathology at Yale School of Medicine and a member of Yale Cancer Center.

Explore further: FDA approval of revolutionary two-drug combo to treat advanced melanoma

Related Stories

FDA approval of revolutionary two-drug combo to treat advanced melanoma

January 27, 2014
Moffitt Cancer Center researchers have laid the groundwork for a revolutionary new combination therapy for the treatment of advanced melanoma – melanoma that cannot be removed surgically or has spread to other areas of ...

New molecular targets identified in some hard-to-treat melanomas

December 17, 2013
Two novel BRAF fusions were identified in melanomas previously considered to be negative for molecular targets, and melanomas with these fusions were found to be potentially sensitive to anticancer drugs called MEK inhibitors, ...

New melanoma driver genes found in largest DNA sequencing study to date

July 29, 2012
(Medical Xpress) -- Yale Cancer Center geneticists, biochemists, and structural biologists have painted the most comprehensive picture yet of the molecular landscape of melanoma, a highly aggressive and often deadly skin ...

Stopping cell migration may help block fibrosis and the spread of cancer

May 21, 2012
(Medical Xpress) -- Discoveries by a Yale-led team of scientists could lead the way for development of new therapies for treating fibrosis and tumor metastasis. The researchers have both uncovered a signaling pathway that ...

New molecular targets identified in some hard-to-treat melanomas provide potential treatment option

December 31, 2013
Stand Up To Cancer (SU2C), the charitable initiative supporting ground-breaking research aimed at getting new cancer treatments to patients in an accelerated timeframe, announces that Jeffrey A. Sosman, M.D., a Stand Up To ...

Awakening genes that suppress tumors

October 10, 2013
(Medical Xpress)—When genes that normally suppress tumor growth are themselves suppressed, cancer cells can grow and proliferate uncontrollably. A new study led by a researcher at Yale University has uncovered the pathway ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.